Drug Trial Radar · NCT07224269
Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Aug 12, 2026
Primary completion
Aug 1, 2027
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- University of IowaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 4, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be a single center, randomized, double-blind, placebo-controlled pilot study to assess the safety and tolerability of terazosin (TZ) at a dose of 5 milligrams (mg) per os (PO) daily for patients with amyotrophic lateral sclerosis (ALS). The primary outcome of this study is to determine whether TZ increases adenosine triphosphate (ATP) levels in ALS. The investigators will measure adverse outcomes, safety, and tolerability of taking TZ. Procedures include blood draws, spirometry, fluorodeoxyglucose-positron emission tomography (FDG-PET) scans, questionnaires, and physical examinations. TZ will be titrated up to 5 mg PO daily. This is a pilot study and is not powered to assess efficacy of this medication. The investigators' hope is that this study will guide future studies of this (and similar) medications for the disease modification of ALS. This study also aims to learn more about how patients produce and use energy and if TZ can help to reverse energy deficits that appear in ALS.
Conditions
- Amyotrophic Lateral Sclerosis
- Adenosine Triphosphate Activities
Interventions
TerazosineDrug
Titrating up to 5 mg PO at bedtime. Trial participants will take terazosin for 12 weeks.
PlaceboDrug
Placebo matching terazosin tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in ATP levelsTime frame: Baseline and 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Iowa Health Care
Iowa City, Iowa · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.